Table 3. Predicting the psychosis-spectrum.

	Outcomes
Predictors	Emergence or persistence of psychosis			Change in total SOPS score			Change in factor 1: Unusual thoughts and experiences			Change in factor 2: Impairment in social, occupational and daily functioning
	Coeff.	z	P	Coeff.	t	P	Coeff.	t	P	Coeff.	t	P
T1 age	0.15	1.76	0.08	0.02	1.25	0.22	0.01	0.31	0.76	0.03	1.53	0.13
Sex	2.12	1.99	0.05	0.25	1.35	0.18	0.59	2.92	0.01	0.01	0.04	0.97
T1 factor 1	1.55	2.38	0.02	−0.18	−1.54	0.13	−0.78	−6.18	0.00	0.00	0.03	0.98
T1 factor 2	−0.17	−0.23	0.82	−0.42	−2.65	0.01	−0.23	−1.38	0.18	−0.50	−2.75	0.01
T1 GAF	−0.04	−1.00	0.32	0.01	1.25	0.22	0.00	−0.34	0.73	0.01	1.19	0.24
T1 mood disorder	1.31	1.06	0.29	0.70	2.55	0.01	1.12	3.79	0.00	0.50	1.61	0.11
T1 anxiety disorder	1.82	1.96	0.05	0.21	0.99	0.33	0.22	0.98	0.33	0.20	0.83	0.41
T1 ADHD	−0.81	−0.90	0.37	0.18	0.85	0.40	−0.02	−0.08	0.93	0.31	1.33	0.19
Lifetime psychotropic use	0.94	1.03	0.30	−0.03	−0.14	0.89	−0.03	−0.14	0.89	0.07	0.29	0.77
T1 global cognition	−2.50	−2.34	0.02	−0.59	−3.37	0.00	−0.39	−2.18	0.03	−0.57	−2.98	0.00
Change in global cognition	−1.21	−1.12	0.26	−0.81	−3.79	0.00	−0.52	−2.37	0.02	−0.83	−3.56	0.00
CNB trials	−1.74	−1.93	0.05	0.02	0.12	0.91	0.07	0.39	0.70	0.16	0.91	0.37

Abbreviations: ADHD, attention-deficit hyperactivity disorder; CNB, Computerized Neurocognitive Battery; Coeff, coefficient; GAF, global assessment of function; SOPS, Scale of Prodromal Symptoms; T1, time 1/initial evaluation.

CNB trials was added as covariate because of possible practice effects and non-uniform total number of trials administered to participants who are evaluated at 2–4 time points. Bolded entries highlight statistical significance.